Novartis' radioligand therapy has performed well against standard-of-care androgen-receptor pathway inhibitor therapy and could potentially be a paradigm shift in the treatment of prostate cancer.
Observers eagerly awaiting the full dataset from the Phase III PSMAfore study of Novartis AG's prostate cancer radioligand therapy Pluvicto have had an early peek at what look like very promising results after all the late-breaking abstracts for the European Society for Medical Oncology (ESMO) meeting in Madrid were released early following a leak.
The Swiss major delivered positive topline data at the end of last year from 469-patient PSMAfore which showed that Pluvicto...
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.
While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.
Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.
The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.
